• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjpharmLink to Publisher's site
Br J Pharmacol. Feb 1996; 117(3): 427–434.
PMCID: PMC1909304

In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

Abstract

1. SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2 ,3-f]indole) displays a high affinity (pK1 7.9) for the cloned human 5-HT2C receptor expressed in HEK 293 cells and the 5-HT2B receptor (pA2 8.9) as measured in the rat stomach fundus preparation. SB 206553 has low affinity for cloned human 5-HT2A receptors expressed in HEK 293 cells (pK1 5.8) and (pK1 < 6) for a wide variety of other neurotransmitter receptors. 2. SB 206553 appears to be a surmountable antagonist of 5-HT-stimulated phosphoinositide hydrolysis in HEK 293 cells expressing the human 5-HT2C receptor (pKB 9.0). 3. The compound potently (ID50 5.5 mg kg-1, p.o., 0.27 mg kg-1, i.v.) inhibited the hypolocomotor response to m-chlorophenylpiperazine (mCPP), a putative model of 5-HT2C/5-HT2B receptor function in vivo. 4. At similar doses (2-20 mg kg-1, p.o.) SB 206553 increased total interaction scores in a rat social interaction test and increased punished responding in a rat Geller-Seifter conflict test. These effects are consistent with the possession of anxiolytic properties. 5. SB 206553 also increased suppressed responding in a marmoset conflict model of anxiety at somewhat higher doses (15 and 20 mg kg-1, p.o.) but also reduced unsuppressed responding. 6. These results suggest that SB 206553 is a potent mixed 5-HT2C/5-HT2B receptor antagonist with selectivity over the 5-HT2A and all other sites studied and possesses anxiolytic-like properties.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408–412. [PMC free article] [PubMed]
  • Barker EL, Westphal RS, Schmidt D, Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem. 1994 Apr 22;269(16):11687–11690. [PubMed]
  • Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT2 receptor subtypes: a family re-united? Trends Pharmacol Sci. 1995 Mar;16(3):105–110. [PubMed]
  • Baxter GS, Murphy OE, Blackburn TP. Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol. 1994 May;112(1):323–331. [PMC free article] [PubMed]
  • Brown AM, Patch TL, Kaumann AJ. The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus. Br J Pharmacol. 1991 Sep;104(1):45–48. [PMC free article] [PubMed]
  • Ceulemans DL, Hoppenbrouwers ML, Gelders YG, Reyntjens AJ. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry. 1985 Sep;18(5):303–305. [PubMed]
  • Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. [PubMed]
  • Clineschmidt BV, Reiss DR, Pettibone DJ, Robinson JL. Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. J Pharmacol Exp Ther. 1985 Dec;235(3):696–708. [PubMed]
  • DeLean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978 Aug;235(2):E97–102. [PubMed]
  • File SE, Hyde JR. Can social interaction be used to measure anxiety? Br J Pharmacol. 1978 Jan;62(1):19–24. [PMC free article] [PubMed]
  • Villarroya M, Gandía L, Lara B, Albillos A, López MG, García AG. Dotarizine versus flunarizine as calcium antagonists in chromaffin cells. Br J Pharmacol. 1995 Jan;114(2):369–376. [PMC free article] [PubMed]
  • Forbes IT, Ham P, Booth DH, Martin RT, Thompson M, Baxter GS, Blackburn TP, Glen A, Kennett GA, Wood MD. 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity. J Med Chem. 1995 Jul 7;38(14):2524–2530. [PubMed]
  • Forbes IT, Kennett GA, Gadre A, Ham P, Hayward CJ, Martin RT, Thompson M, Wood MD, Baxter GS, Glen A, et al. N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist. J Med Chem. 1993 Apr 16;36(8):1104–1107. [PubMed]
  • GELLER I, KULAK JT, Jr, SEIFTER J. The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia. 1962 Oct 31;3:374–385. [PubMed]
  • Hamblin MW, Metcalf MA. Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143–148. [PubMed]
  • Higgins GA, Jones BJ, Oakley NR, Tyers MB. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology (Berl) 1991;104(4):545–551. [PubMed]
  • Kennett GA, Bailey F, Piper DC, Blackburn TP. Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl) 1995 Mar;118(2):178–182. [PubMed]
  • Kennett GA, Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol. 1988 May;94(1):137–147. [PMC free article] [PubMed]
  • Kennett GA, Pittaway K, Blackburn TP. Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl) 1994 Feb;114(1):90–96. [PubMed]
  • Loric S, Launay JM, Colas JF, Maroteaux L. New mouse 5-HT2-like receptor. Expression in brain, heart and intestine. FEBS Lett. 1992 Nov 9;312(2-3):203–207. [PubMed]
  • Maksay G. Partial and full agonists/inverse agonists affect [35S]TBPS binding at different occupancies of central benzodiazepine receptors. Eur J Pharmacol. 1993 Aug 15;246(3):255–260. [PubMed]
  • Pompeiano M, Palacios JM, Mengod G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res. 1994 Apr;23(1-2):163–178. [PubMed]
  • Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S. Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1469–1478. [PubMed]
  • Schmuck K, Ullmer C, Engels P, Lübbert H. Cloning and functional characterization of the human 5-HT2B serotonin receptor. FEBS Lett. 1994 Mar 28;342(1):85–90. [PubMed]
  • Schoeffter P, Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn Schmiedebergs Arch Pharmacol. 1989 Jun;339(6):675–683. [PubMed]
  • To ZP, Bonhaus DW, Eglen RM, Jakeman LB. Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain. Br J Pharmacol. 1995 May;115(1):107–116. [PMC free article] [PubMed]
  • Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991 Apr 18;350(6319):610–614. [PubMed]
  • Westphal RS, Sanders-Bush E. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol. 1994 Nov;46(5):937–942. [PubMed]
  • Whitton P, Curzon G. Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology (Berl) 1990;100(1):138–140. [PubMed]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • BioAssay
    BioAssay
    PubChem BioAssay links
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...